Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immunoglobulin
Pharma
CSL cuts FY26 revenue projection by $600M, writes off $5B
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion and is taking a $5 billion asset impairment.
Kevin Dunleavy
May 11, 2026 11:30am
Travere's bid to gain new approval for Filspari hits FDA hitch
Jan 14, 2026 11:22am
Kedrion wins FDA nod for immunodeficiency disorder treatment
Sep 29, 2025 11:39am
Grifols deflects private equity firm's potential takeover offer
Nov 20, 2024 10:13am
FDA grants Calliditas full nod for kidney disease drug Tarpeyo
Dec 20, 2023 5:24pm
Novartis shows strong Fabhalta results in another blood disorder
Dec 11, 2023 11:20am
